CORRECTION: An investigational individualized neoantigen therapy studied in patients with high-risk melanoma is a collaboration between Moderna and Merck. A previous version of this article referred to it as Moderna’s therapy.
Moderna and Merck & Co. on Monday released new results from a trial evaluating the companies’ mRNA-based investigational individualized neoantigen therapy in combination with Merck’s Keytruda in patients with high-risk melanoma. The combined therapy demonstrated a meaningful improvement in distant metastasis-free survival, a key secondary endpoint of the study, the companies said in a release. The results “add to the emerging picture of how individualized neoantigen therapy may advance melanoma treatment and the promise it may hold for other types of cancer,” Moderna senior vice president Dr. Kyle Holen said in a statement. The new data are being presented for the first time Monday at the American Society of Clinical Oncology annual meeting in Chicago. Moderna shares are up 0.2% on Monday, while Merck shares are up 0.7%.